Amphastar Pharmaceuticals’ (AMPH) “Neutral” Rating Reiterated at Piper Sandler

Piper Sandler reissued their neutral rating on shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) in a report issued on Monday morning,Benzinga reports. They currently have a $21.00 price objective on the stock, down from their prior price objective of $25.00.

A number of other equities research analysts also recently weighed in on AMPH. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Friday, May 8th. Wells Fargo & Company lowered their price target on Amphastar Pharmaceuticals from $34.00 to $30.00 and set an “overweight” rating for the company in a report on Friday, February 27th. Barclays lowered their price target on Amphastar Pharmaceuticals from $30.00 to $23.00 and set an “equal weight” rating for the company in a report on Wednesday, April 8th. Jefferies Financial Group reiterated a “hold” rating and issued a $22.00 price target (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Tuesday, April 21st. Finally, Weiss Ratings downgraded Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, April 10th. One equities research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Amphastar Pharmaceuticals has an average rating of “Hold” and an average price target of $26.33.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ AMPH opened at $18.32 on Monday. Amphastar Pharmaceuticals has a twelve month low of $17.03 and a twelve month high of $31.26. The company has a current ratio of 3.85, a quick ratio of 2.82 and a debt-to-equity ratio of 0.79. The company has a market capitalization of $807.73 million, a price-to-earnings ratio of 11.04, a price-to-earnings-growth ratio of 2.84 and a beta of 0.97. The business has a 50 day simple moving average of $20.35 and a 200-day simple moving average of $24.40.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.28). Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. The firm had revenue of $171.17 million during the quarter, compared to the consensus estimate of $173.46 million. As a group, equities research analysts expect that Amphastar Pharmaceuticals will post 2.93 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. grew its stake in Amphastar Pharmaceuticals by 24.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company’s stock worth $60,000 after buying an additional 435 shares during the last quarter. Farther Finance Advisors LLC grew its stake in Amphastar Pharmaceuticals by 46.3% during the 4th quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock worth $37,000 after buying an additional 437 shares during the last quarter. ProShare Advisors LLC grew its stake in Amphastar Pharmaceuticals by 5.3% during the 4th quarter. ProShare Advisors LLC now owns 9,083 shares of the company’s stock worth $243,000 after buying an additional 457 shares during the last quarter. Los Angeles Capital Management LLC grew its stake in Amphastar Pharmaceuticals by 2.4% during the 4th quarter. Los Angeles Capital Management LLC now owns 19,397 shares of the company’s stock worth $478,000 after buying an additional 459 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in Amphastar Pharmaceuticals by 37.8% during the 4th quarter. GAMMA Investing LLC now owns 1,685 shares of the company’s stock worth $45,000 after buying an additional 462 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.